Moderna (MRNA) Q4 2024 Earnings Call Transcript

Moderna reported 2024 revenue of $3.2 billion (Q4 $966 million), a full‑year net loss of $3.6 billion and ended the year with $9.5 billion of cash after achieving roughly $2.6 billion of cost savings versus 2023; cost of sales was elevated in Q4 due to inventory write‑downs (~$193m) and a $238m non‑cash contract termination tied to manufacturing resizing. The company is now a multiproduct commercial player with Spikevax and newly approved mResvia, has filed three respiratory vaccines (next‑gen COVID mRNA‑1283 with a U.S. PDUFA on May 31 and an RSV 18–59 filing with a PDUFA on June 12), and is prioritizing 10 high‑value programs (TAM >$30bn) including INT (adjuvant melanoma), CMV (interim did not meet early efficacy criteria but final readout is expected in 2025) and norovirus (Northern Hemisphere enrollment complete; U.S. trial on FDA clinical hold after one GBS case, which the company says is under investigation and should have limited timeline impact). For 2025 Moderna guides revenue of $1.5–$2.5 billion, GAAP expenses of ~$6.4 billion (cash costs ~$5.5 billion), expects year‑end cash of about $6 billion, and says vaccination rates, market share, the size of the RSV market and timing/licensure of new manufacturing sites will determine whether pipeline approvals can drive the company back to cash break‑even by 2028.

Analysis

Moderna reported 2024 revenue of $3.2 billion with Q4 revenue of $966 million and a full-year net loss of $3.6 billion (EPS -$9.28); the company finished 2024 with $9.5 billion in cash after achieving approximately $2.6 billion of operating cost reductions versus 2023. Q4 net product sales were $0.9 billion (U.S. $0.2 billion; ex-U.S. $0.7 billion), Spikevax accounted for the vast majority of sales and newly approved mResvia contributed $25 million for the year.

Q4 cost of sales was $739 million and included $193 million of inventory write-downs and a $238 million noncash charge for termination of a contract manufacturing agreement, driving cost of sales to 79% of product sales (53% excluding resizing); full-year cost of sales was $1.5 billion (47%). R&D totaled $4.5 billion and SG&A $1.2 billion in 2024; management guides 2025 revenue of $1.5–$2.5 billion, GAAP expenses of ~$6.4 billion (cash costs ~$5.5 billion), and expects ~ $6 billion year-end cash.

Pipeline progress is material but binary: Moderna filed three respiratory vaccines (next‑gen COVID mRNA‑1283 with a U.S. PDUFA on May 31 and an RSV 18–59 filing with a PDUFA on June 12), reported multiple positive phase‑3 readouts, and is prioritizing 10 programs targeting a >$30 billion TAM. Near‑term risks that can move the guidance range materially are the PDUFA outcomes, the CMV final analysis (expected in 2025), the FDA clinical hold on the norovirus U.S. trial after one Guillain‑Barré case, and timing/licensure of new manufacturing sites (U.K., Canada, Australia) that affect supply and cost dynamics.

Key Decisions for Investors

• Defer material position increases until PDUFA outcomes (May 31 for mRNA‑1283, June 12 for RSV) and CMV final readout provide clearer commercialization visibility,
• Monitor resolution of the FDA clinical hold on norovirus and any additional safety signals closely; adverse findings would increase downside risk to the 2025 guidance,
• Reassess exposure sizing given the wide 2025 revenue range ($1.5–$2.5B) and expected year‑end cash of ~$6B; consider hedging or reducing exposure if manufacturing licensure delays or weaker vaccination rates emerge,
• If approvals are confirmed and inventory/write‑downs trend lower, consider incremental accumulation on confirmed commercial uptake and demonstrated margin improvement